Brief: Neubase Therapeutics Announces Positive Preclinical In Vivo Data For Patrol-Enabled Anti-Gene For The Treatment Of Myotonic Dystrophy Type 1
16/12/2020 11:32
Dec 16 (Reuters) - NeuBase Therapeutics Inc NBSE.O :
* NEUBASE THERAPEUTICS ANNOUNCES POSITIVE PRECLINICAL IN
VIVO DATA
FOR PATROL™-ENABLED ANTI-GENE FOR THE TREATMENT OF MYOTONIC
DYSTROPHY TYPE 1
Source text for Eikon: ID:nGNX7C6W3Z
Further company coverage: NBSE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NeuBase Therapeutics
See all newsBrief: Neubase Therapeutics, On May 2, Was Notified By Nasdaq On Not Regained Compliance With Minimum Bid Price Requirement
Brief: Neubase Therapeutics Announces Receipt Of Notice From Nasdaq
U.S. STOCKS ON THE MOVE-TPG, R1 RCM, Zoom
U.S. STOCKS ON THE MOVE-Micron, Krystal Biotech, Pilgrim's Pride
U.S. STOCKS ON THE MOVE-Domino's Pizza, Voyager, Freshpet